Department of Radiology, Huaxi MR Research Center (HMRRC), and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Innovation Center of Nanomedicine (iCONM), Kawasaki Institute of Industrial Promotion, Kawasaki, Japan.
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2024 Jul-Aug;16(4):e1988. doi: 10.1002/wnan.1988.
Polymer-drug conjugates and polymer-protein conjugates have been pivotal in the realm of drug delivery systems for over half a century. These polymeric drugs are characterized by the conjugation of therapeutic molecules or functional moieties to polymers, enabling a range of benefits including extended circulation times, targeted delivery, controlled release, and decreased immunogenicity. This review delves into recent advancements and challenges in the clinical translations and preclinical studies of polymer-drug conjugates and polymer-protein conjugates. The design principles and functionalization strategies crucial for the development of these polymeric drugs were explored followed by the review of structural properties and characteristics of various polymer carriers. This review also identifies significant obstacles in the clinical translation of polymer-drug conjugates and provides insights into the directions for their future development. This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease.
聚合物-药物偶联物和聚合物-蛋白偶联物在半个多世纪的药物输送系统领域中一直起着关键作用。这些聚合物药物的特点是将治疗分子或功能部分与聚合物连接起来，从而具有一系列的益处，包括延长循环时间、靶向递送、控制释放和降低免疫原性。本综述深入探讨了聚合物-药物偶联物和聚合物-蛋白偶联物在临床转化和临床前研究中的最新进展和挑战。探讨了开发这些聚合物药物的关键设计原则和功能化策略，接着综述了各种聚合物载体的结构特性和特点。本文还确定了聚合物-药物偶联物在临床转化中的重大障碍，并为其未来发展方向提供了见解。本文属于以下类别：治疗方法和药物发现 > 用于肿瘤疾病的纳米医学。
